0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Relationship between Dideoxyinosine Exposure, CD4 Counts, and p24 Antigen Levels in Human Immunodeficiency Virus Infection: A Phase I Trial

George L. Drusano, MD; Geoffrey J. Yuen, PharmD; John S. Lambert, MD; Mindell Seidlin, MD; Raphael Dolin, MD; and Fred T. Valentine, MD
[+] Article, Author, and Disclosure Information

Grant Support: In part by a grant from the Bristol-Myers-Squibb Company.

Requests for Reprints: George L. Drusano, MD, Program of Clinical Pharmacology, Division of Infectious Diseases, University of Maryland, 10 South Pine Street, Baltimore, MD 21201.

Current Author Addresses: Dr. Drusano: Program of Clinical Pharmacology, Division of Infectious Diseases, University of Maryland, 10 South Pine Street, Baltimore, MD 21201.

Dr. Yuen: The University of Maryland School of Pharmacy, 20 North Pine Street, Baltimore, MD 21201.

Drs. Lambert and Dolin: University of Rochester Medical Center, Box 689, 601 Elmwood Avenue, Rochester, NY 14642.

Dr. Seidlin: Bellevue Hospital Center, AIDS Unit, 27th Street and First Avenue, Room 12-E-12, New York, NY 10016.

Dr. Valentine: Department of Medicine, NYU Medical Center, 550 First Avenue, New York, NY 10016.


© 1992 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1992;116(7):562-566. doi:10.7326/0003-4819-116-7-562
Text Size: A A A

Objective: To determine the relation between exposure to dideoxyinosine (ddl) and increased CD4 cell counts and suppression of serum p24 antigen in patients infected with the human immunodeficiency virus (HIV).

Design: Open-label, phase I study.

Setting: Two university hospitals. Patients were studied in both inpatient and outpatient settings.

Patients: Of 36 HIV-infected patients enrolled, 18 had adequate pharmacokinetic information for analysis.

Intervention: Dideoxyinosine was administered intravenously every 12 hours for 2 weeks. Patients were switched to oral administration at twice the intravenous dose. Pharmacokinetic profiles were obtained twice during each period. A 40-fold range of dose was examined.

Measurements: CD4-positive T-lymphocyte counts and serum p24 antigen levels were determined. Plasma area under the ddl concentration-time curve was determined for a single dose and at steady state.

Results: Increases in CD4-positive T-lymphocyte counts were independent of ddl exposure and were proportional to the starting CD4 count. Suppression of circulating p24 antigen was influenced by cumulative exposure to ddl and was statistically significant.

Conclusions: The CD4-positive T-lymphocyte count increased at low ddl concentrations or exposures; the extent of this increase was directly proportional to the patient's CD4 count at the start of therapy. Suppression of p24 antigen was related to cumulative exposure to ddl. Therapeutic responses can probably be obtained with ddl, while minimizing long-term toxicity, using daily doses of 10 mg/kg body weight, or less.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)